Should I order a JAK2 mutation test for a patient currently receiving intravenous iron for iron‑deficiency anemia?

JAK2 Testing in Patients Receiving Intravenous Iron

Yes, you can and should order JAK2 mutation testing in a patient receiving IV iron if there is clinical suspicion of a myeloproliferative neoplasm, particularly polycythemia vera, regardless of their current iron therapy status. The presence of iron deficiency does not exclude polycythemia vera and may actually be a presenting feature of the disease.

Clinical Context: Iron Deficiency and Polycythemia Vera

Iron deficiency is frequently present at diagnosis in polycythemia vera patients and does not preclude JAK2 testing. 1 In fact, patients with PV commonly exhibit iron deficiency at presentation, which can mask the true elevation in hemoglobin/hematocrit by limiting red cell production. 2

• Iron deficiency confounds accurate interpretation of hemoglobin/hematocrit levels in suspected PV, as hemoglobin may be falsely lowered when iron stores are depleted. 2
• Microcytosis in the setting of elevated or high-normal hemoglobin should raise suspicion for PV with secondary iron deficiency from increased erythropoiesis. 1
• The WHO diagnostic criteria acknowledge that formal PV diagnosis may require demonstration of meeting hemoglobin/hematocrit thresholds after iron replacement, but this does not prevent ordering JAK2 testing during the iron-deficient state. 2

When to Order JAK2 Testing

JAK2 V617F should be the first molecular test ordered in any patient suspected of having a myeloproliferative neoplasm. 2

Specific indications include:

• Elevated hemoglobin/hematocrit: Men with Hb ≥18.5 g/dL or Hct >49%; women with Hb ≥16.5 g/dL or Hct >48%. 2, 3
• Sustained hemoglobin rise: An increase of ≥2 g/dL reaching ≥17 g/dL in men or ≥15 g/dL in women. 2, 3
• Thrombocytosis: Platelet count ≥450 × 10⁹/L, especially with other MPN features. 2
• Unexplained erythrocytosis or splenomegaly with or without other cytopenias. 2
• Aquagenic pruritus (intense itching after water contact), which is characteristic of PV. 2

Diagnostic Algorithm

Step 1: Order JAK2 V617F mutation testing first

• JAK2 V617F detects >90–95% of polycythemia vera cases and serves as a major WHO diagnostic criterion. 3, 4
• Testing can and should be performed while the patient is receiving IV iron therapy. 2

Step 2: If JAK2 V617F is negative

• Order JAK2 exon 12 mutation testing, which identifies an additional 2–3% of PV cases. 2, 3
• JAK2 exon 12 mutations fulfill the second major WHO diagnostic criterion. 3

Step 3: Complete diagnostic work-up

• Serum erythropoietin level: Low or low-normal EPO (<reference range) is a WHO minor criterion supporting primary polycythemia. 2, 3
• Bone marrow biopsy: Shows hypercellularity with trilineage growth (panmyelosis) and pleomorphic megakaryocytes; this is a WHO minor criterion. 2, 3
• Iron studies: Ferritin and transferrin saturation to document iron deficiency and guide replacement. 2, 5

WHO Diagnostic Criteria for Polycythemia Vera

Diagnosis requires either:

1. Both major criteria + ≥1 minor criterion, OR
2. First major criterion + ≥2 minor criteria 3

Major Criteria:

• Elevated Hb/Hct (thresholds above) 2, 3
• Presence of JAK2 V617F or JAK2 exon 12 mutation 2, 3

Minor Criteria:

• Bone marrow hypercellularity with trilineage growth 2, 3
• Subnormal serum erythropoietin 2, 3
• Endogenous erythroid colony formation in vitro 2, 3

Critical Pitfalls to Avoid

Do not delay JAK2 testing until after iron repletion is complete. The mutation test is independent of iron status and can be ordered immediately when clinical suspicion exists. 2, 3

Do not assume iron deficiency anemia explains all findings. Up to 30% of confirmed PV patients may have erythropoietin values within the normal range, and iron deficiency is common at PV diagnosis. 3, 1

Do not rely solely on low erythropoietin to diagnose PV. Low EPO is only a minor WHO criterion and cannot establish the diagnosis without meeting major criteria. 3

Do not accept a hemoglobin of 16 g/dL in men as meeting the first major criterion. The threshold is ≥18.5 g/dL in men (or ≥17 g/dL with a sustained ≥2 g/dL rise). 2, 3

Impact of Iron Therapy on MPN Phenotype

Intravenous iron administration does not interfere with JAK2 mutation detection but may alter the clinical phenotype of the disease. 1

• In JAK2-mutant mice with PV phenotype, parenteral iron injections decreased platelet counts and further increased hemoglobin/hematocrit. 1
• Iron availability primarily affects premegakaryocyte-erythrocyte progenitors, which constitute the iron-responsive stage of hematopoiesis in JAK2-mutant states. 1
• After iron replacement, hemoglobin may rise and unmask the true degree of erythrocytosis, confirming PV diagnosis. 2

Practical Recommendation

Order JAK2 V617F testing now in any patient receiving IV iron who has:

• Elevated or high-normal hemoglobin/hematocrit for age and sex 3
• Unexplained thrombocytosis or leukocytosis 2
• Splenomegaly or aquagenic pruritus 2
• Microcytosis with elevated hemoglobin (suggesting iron-deficient PV) 1

The test result will guide further diagnostic evaluation and does not require waiting for completion of iron therapy. 2, 3